Year-end Sale % OFF 
Abstract
Expression of alpha-1-antitrypsin (AAT) in tumour cells of 102 surgically resected lung adenocarcinomas was examined by immunohistochemical method using anti-AAT antiserum. While only 13 cases (13%) were negative for AAT expression, 89 cases (87%) contained AAT at varying degrees. The degree of AAT-positive tumour cells was significantly higher in advanced cases than in early cases. Clinical follow-up study of the patients, particularly in stage I, showed that strongly AAT-positive cases have poor prognosis than weak-to-moderately AAT-positive or AAT-negative cases. Thus, AAT expression status in tumour cells of lung adenocarcinoma may be a biological marker of prognostic significance in regard to tumour growth.
Highlights
With few exceptions, several reports have shown that cases with AAT expression in tumour cells had worse prognosis than those without AAT expression, suggesting that AAT production in tumours cells may correlate with more aggressive behaviour in some gastrointestinal cancers (Tahara et al, 1984; Wittekind et al, 1986; Karashima et al, 1990)
Karashima et al (1990) reported that the incidence of AAT expression was markedly higher in advanced cases than in early cases, and that AAT-positive cases had a poor prognosis than AAT-negative cases, in early stages
Our results showed that AAT expression in tumour cells of lung adenocarcinoma is strongly associated with tumour growth and prognosis
Summary
With few exceptions, several reports have shown that cases with AAT expression in tumour cells had worse prognosis than those without AAT expression, suggesting that AAT production in tumours cells may correlate with more aggressive behaviour in some gastrointestinal cancers (Tahara et al, 1984; Wittekind et al, 1986; Karashima et al, 1990). AAT expression in lung cancer has not been studied yet. In order to clarify the clinicopathological significance of AAT expression in lung cancer, the authors performed a preliminary immunohistochemical study of its incidence in lung adenocarcinoma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
